search
Back to results

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (OneStep-1)

Primary Purpose

Diabetic Foot Infection

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Topical pexiganan cream 0.8%
Topical placebo cream
Standard wound care
Sponsored by
Dipexium Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Infection focused on measuring Diabetic Foot Ulcer Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diabetes mellitus.
  2. Male or female at least 18 years old.
  3. Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent.
  4. Subject is to be treated on an outpatient basis.
  5. Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement.
  6. Localized mild infection of the ulcer.
  7. The diagnosis of mild infection must be confirmed immediately following debridement at Baseline.
  8. Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.

Exclusion Criteria:

  1. IDSA-defined moderate infection.
  2. IDSA-defined severe infection.
  3. Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.
  4. > 1 infected foot ulcer.
  5. Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
  6. Subject has received a systemic antibiotic within 48 hours prior to Screening.
  7. Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
  8. Bone or joint involvement is suspected based on clinical examination or plain X-ray.
  9. Clinically significant peripheral arterial disease requiring vascular intervention.
  10. Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Topical placebo control

Topical pexiganan cream 0.8%

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants With Clinical Response
The numbers of participants with Clinical Response, defined as resolution of infection, are reported.

Secondary Outcome Measures

Number of Participants With Microbiological Success
The numbers of participants with Microbiological Response, defined as eradication of all initial pathogens, are reported.
Number of Participants With Treatment-emergent Adverse Events (TEAE)
The numbers of participants with TEAEs, including those with Serious TEAEs, are reported

Full Information

First Posted
April 27, 2012
Last Updated
May 19, 2017
Sponsor
Dipexium Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01590758
Brief Title
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Acronym
OneStep-1
Official Title
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dipexium Pharmaceuticals, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care, as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Infection
Keywords
Diabetic Foot Ulcer Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
189 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Topical placebo control
Arm Type
Placebo Comparator
Arm Title
Topical pexiganan cream 0.8%
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Topical pexiganan cream 0.8%
Other Intervention Name(s)
MSI-78
Intervention Description
14 days of treatment
Intervention Type
Drug
Intervention Name(s)
Topical placebo cream
Intervention Description
14 days of treatment
Intervention Type
Other
Intervention Name(s)
Standard wound care
Intervention Description
14 days of treatment
Primary Outcome Measure Information:
Title
Number of Participants With Clinical Response
Description
The numbers of participants with Clinical Response, defined as resolution of infection, are reported.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Number of Participants With Microbiological Success
Description
The numbers of participants with Microbiological Response, defined as eradication of all initial pathogens, are reported.
Time Frame
28 days
Title
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Description
The numbers of participants with TEAEs, including those with Serious TEAEs, are reported
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetes mellitus. Male or female at least 18 years old. Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent. Subject is to be treated on an outpatient basis. Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement. Localized mild infection of the ulcer. The diagnosis of mild infection must be confirmed immediately following debridement at Baseline. Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot. Exclusion Criteria: IDSA-defined moderate infection. IDSA-defined severe infection. Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware. > 1 infected foot ulcer. Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment. Subject has received a systemic antibiotic within 48 hours prior to Screening. Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer. Bone or joint involvement is suspected based on clinical examination or plain X-ray. Clinically significant peripheral arterial disease requiring vascular intervention. Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael H. Silverman, MD
Organizational Affiliation
BioStrategics Consulting Ltd
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Glendale
State/Province
Arizona
Country
United States
City
Mesa
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Jonesboro
State/Province
Arkansas
Country
United States
City
Bakersfield
State/Province
California
Country
United States
City
Fair Oaks
State/Province
California
Country
United States
City
Fresno
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Boynton Beach
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
North Miami Beach
State/Province
Florida
Country
United States
City
South Miami
State/Province
Florida
Country
United States
City
Lexington
State/Province
Kentucky
Country
United States
City
Baltimore
State/Province
Maryland
Country
United States
City
Cambridge
State/Province
Massachusetts
Country
United States
City
Missoula
State/Province
Montana
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Emerson
State/Province
New Jersey
Country
United States
City
Greenville
State/Province
North Carolina
Country
United States
City
Toledo
State/Province
Ohio
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
Aiken
State/Province
South Carolina
Country
United States
City
Baytown
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
McAllen
State/Province
Texas
Country
United States
City
McKinney
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

We'll reach out to this number within 24 hrs